HIMS climbs over 4% after unveiling four new Benefits platform partnerships

Traders Union
All News
Stocks
Hims & hers health surges 4.03% today

Highlights

Hims & Hers Health will report third-quarter earnings on November 9, 2026, with analysts expecting earnings per share of $0.06 and a consensus Hold rating.
The company expanded its Benefits platform to 14 programs by adding partnerships with Grüns, Medjet, Tonal, and Viome, broadening subscriber health services.
Shares of Hims & Hers Health last traded at $25.03 after significant intraday volatility, with technical indicators suggesting ongoing selling pressure, oversold extremes, and a projected range of $22.2 to $27.86.

Subscriber service growth and earnings hold drive muted analyst expectations

Hims & Hers Health is set to announce its third-quarter earnings on November 9, 2026. On November 5, 2026, the company expanded its Benefits platform by partnering with Grüns, Medjet, Tonal, and Viome, raising the program count to 14 and broadening its range of subscriber health services. Analyst expectations for the upcoming quarter place earnings per share at $0.06, consistent with the prior year, and the consensus rating is Hold.

Anton Kharitonov, expert at Traders Union, points out that HIMS remains under strong selling pressure despite recent gains. He cautions that trading below all key moving averages is a bearish sign across every timeframe. Weak technicals, including a dominant number of sell signals, support only a tentative potential for a short-lived rally. Kharitonov sees news of new partners as insufficient to shift the prevailing negative trend. "Oversold oscillators may indicate a technical bounce, but in my view, ongoing pressure and the risk of a breakdown below $22.95 make the downside scenario far more likely," he says.

Viktoras Karapetjanc, expert at Traders Union, highlights Hims & Hers Health's robust expansion of its Benefits platform with four new partners as a clear fundamental strength. He believes the company's ability to scale subscriber health offerings positions it for further growth and future leadership in the sector. Karapetjanc notes that stable EPS expectations and a Hold rating indicate the market is yet to fully price in the platform's long-term value. "Strong program growth and positive demand cues reinforce my view that HIMS is set for further upside once the current volatility subsides," he states.

Jainam Mehta, market strategist, observes that HIMS oscillates between support at $22.95 and resistance at $26.42 within a volatile setup. He sees mixed technical indicators, with oversold readings creating space for a tactical rebound. Mehta suggests traders monitor for a breakout above resistance, which could trigger short-term momentum. "If a sudden spike in sentiment lifts HIMS above $26.42, a fast-trade long setup could pay off — but below $22.95, capital protection is key," he advises.

Divided technical momentum emerges as oversold extremes clash with resistance

HIMS is currently trading below its 20-day, 50-day, and 200-day moving averages ($28.18, $28.54, and $26.93, respectively), indicating sustained selling pressure across short-, medium-, and long-term trends. The nearest key levels are $26.42 as short-term resistance and $22.95 as support, while distant overhead levels reinforce the prevailing bearish outlook. Broadly bearish momentum persists: MACD signals a sell, ADX is neutral, the Relative Strength Index (RSI) is neutral, and both the Stochastic RSI and Commodity Channel Index (CCI) are in the oversold zone. This mixed technical setup reflects possible oversold rebound risk, even as sellers dominate intraday momentum according to Bull/Bear Power. The Awesome Oscillator also signals ongoing selling pressure. After opening with an upside gap of about $2.25 (9.35%), the stock closed up $0.97 (4.03%) at $25.03, showing heavy intraday volatility of 15.12%. Despite intraday upward movement, strong selling signals and oversold oscillator extremes create a divided technical backdrop.

Earlier, analysts noted that Hims & Hers Health continued to face persistent downside pressure, with bearish technical signals dominating the outlook. The latest data confirm this weak trend, and with volatility still elevated, traders should watch for potential breaks below $22.95 to assess further downside risk in the days ahead.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.